GWM
CRL icon

Geneos Wealth Management’s Charles River Laboratories CRL Stock Holding History

Geneos Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Sell
699
-1
-0.1% -$178 ﹤0.01% 1075
2026
Q1 		$121K Sell
700
-41
-6% -$7.6K ﹤0.01% 1118
2025
Q4 		$148K Buy
741
+552
+292% +$100K ﹤0.01% 1030
2025
Q3 		$29.6K Sell
189
-104
-35% -$16.5K ﹤0.01% 1576
2025
Q2 		$44.5K Buy
293
+145
+98% +$19.3K ﹤0.01% 1636
2025
Q1 		$22.3K Buy
148
+40
+37% +$6.71K ﹤0.01% 1900
2024
Q4 		$19.9K Sell
108
-9,777
-99% -$1.88M ﹤0.01% 1727
2024
Q3 		$1.95M Buy
9,885
+862
+10% +$179K 0.07% 286
2024
Q2 		$1.86M Buy
9,023
+1,394
+18% +$316K 0.08% 258
2024
Q1 		$2.07M Buy
7,629
+2,617
+52% +$625K 0.09% 245
2023
Q4 		$1.18M Sell
5,012
-12
-0.2% -$2.36K 0.06% 299
2023
Q3 		$985K Buy
5,024
+199
+4% +$40.9K 0.05% 326
2023
Q2 		$1.01M Buy
4,825
+530
+12% +$105K 0.05% 313
2023
Q1 		$867K Buy
4,295
+4,236
+7,180% +$960K 0.05% 322
2022
Q4 		$12.9K Hold
59
– – ﹤0.01% 1464
2022
Q3 		$11K Hold
59
– – ﹤0.01% 1485
2022
Q2 		$12K Hold
59
– – ﹤0.01% 1876
2022
Q1 		$16K Hold
59
– – ﹤0.01% 1895
2021
Q4 		$22K Buy
59
+55
+1,375% +$21.4K ﹤0.01% 1838
2021
Q3 		$1K Hold
4
– – ﹤0.01% 2720
2021
Q2 		$1K Sell
4
-695
-99% -$232K ﹤0.01% 2736
2021
Q1 		$232K Buy
699
+65
+10% +$18.1K 0.01% 907
2020
Q4 		$1K Buy
+634
New +$151K ﹤0.01% 2773
2019
Q4 		– Sell
-8
Closed -$1K – 2546
2019
Q3 		$1K Buy
+8
New +$1.07K ﹤0.01% 2381
2017
Q2 		– Sell
-18
Closed -$1K – 2087
2017
Q1 		$1K Sell
18
-9
-33% -$764 ﹤0.01% 1967
2016
Q4 		$2K Hold
27
– – ﹤0.01% 1833
2016
Q3 		$2K Buy
+27
New +$2.26K ﹤0.01% 1756

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Geneos Wealth Management's CRL Position: Q2 2026 in Review

Geneos Wealth Management reduced its Charles River Laboratories (CRL) stake by 0.14% in Q2 2026, selling an estimated $178 and leaving 699 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

Geneos Wealth Management first reported a position in CRL in Q3 2016 and has held it in 27 quarters since. The position peaked at $2.07M in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Geneos Wealth Management held 699 shares of Charles River Laboratories worth $159K as of Q2 2026.
  • Geneos Wealth Management sold 1 Charles River Laboratories share in Q2 2026, an estimated $178.
  • Charles River Laboratories made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1075 holding.
  • Geneos Wealth Management first reported a position in Charles River Laboratories in Q3 2016 and has held it in 27 quarters since.
  • Geneos Wealth Management's Charles River Laboratories position peaked at $2.07M in Q1 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.